What GLP-1 Medications Are and How They Work
GLP-1 (glucagon-like peptide-1) receptor agonists — including semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro, which also targets GIP receptors) — were originally developed for type 2 diabetes and are now widely prescribed for weight management. They work by mimicking the GLP-1 hormone naturally released after eating: they slow gastric emptying, reduce appetite centrally in the brain, improve insulin sensitivity, and reduce post-meal glucose spikes. They have remarkable efficacy for weight loss — clinical trials show 15–20% body weight reduction with semaglutide, unprecedented for a pharmacological intervention. For women, the implications are significant and hormonal.
PCOS: The Most Relevant Women's Health Application
The intersection of GLP-1 medications and PCOS is one of the most clinically significant in women's health. PCOS, particularly the insulin-resistant phenotype, is precisely the metabolic profile that GLP-1 medications address best. Multiple studies and clinical reports document that semaglutide and liraglutide in PCOS women improve insulin sensitivity, reduce androgens, restore menstrual regularity, and improve ovulatory function. A 2023 randomised controlled trial found that semaglutide outperformed lifestyle intervention alone for restoring ovulation in anovulatory PCOS women. For women with PCOS and BMI above 30 who have not responded adequately to metformin and lifestyle changes, GLP-1 medications are a legitimate and increasingly evidenced option.
Fertility: The Unexpected Pregnancy Risk
One of the most under-publicised risks of GLP-1 medications for women of reproductive age is inadvertent pregnancy. As these drugs restore ovulation in women with PCOS and anovulatory cycles, women who had irregular or absent periods — and who may have been using absence of periods as informal contraception — can suddenly begin ovulating again. Multiple cases of unintended pregnancy in women on semaglutide have been reported. Additionally, semaglutide reduces the efficacy of oral contraceptive pills by slowing gastric absorption (the pill may pass through the stomach too quickly). Women of reproductive age on GLP-1 medications must use non-oral contraception (IUD, implant, injection, barrier methods) and GLP-1 medications must be stopped at least 2 months before attempting pregnancy.
The Menstrual Cycle During GLP-1 Treatment
Weight loss of any mechanism can temporarily disrupt the menstrual cycle by altering oestrogen metabolism (adipose tissue is an oestrogen-producing organ, and rapid loss of adipose tissue can cause oestrogen to drop). Women starting GLP-1 medications may experience cycle irregularity in the first 3–6 months, particularly with rapid early weight loss. This is not typically cause for concern, but it is worth tracking. As weight stabilises and insulin sensitivity improves (particularly in PCOS), cycles typically regularise. For women experiencing new cycle irregularity on GLP-1 therapy without a prior PCOS diagnosis, thyroid function and prolactin testing rule out other causes.
Access in the US and Europe
In the US, semaglutide for weight management (Wegovy) is covered by Medicare for people with cardiovascular disease risk (since 2024) and increasingly by commercial insurers, but coverage varies significantly by plan and state. Out-of-pocket cost without insurance is approximately $900–$1,300 per month. In the UK, tirzepatide (Mounjaro) received NICE approval for weight management in 2023 with NHS roll-out ongoing through specialist weight management services; access outside these services requires private prescription (approximately £150–£250/month). EU countries vary, with Germany and France having the broadest coverage pathways. Access inequity for these medications is a genuine concern, as the women who most need them (those with significant insulin resistance and PCOS) are not always those with the best insurance or income.
Medical Disclaimer
This article is written for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.
Dr. Priya Anand
MBBS, DGO
All TryHerCare articles are written and reviewed by qualified medical professionals. Our content is clinician-reviewed to ensure accuracy and clinical relevance.
